Javascript must be enabled to continue!
Differential responses of receptor tyrosine kinases C‐Met and EGFR in mice
View through CrossRef
In previous studies, we have demonstrated the critical roles of EGFR and HGFR (c‐Met) for liver regeneration and for conversion of hepatocytes to cholangiocytes by a “clean” partial hepatectomy model, in which hepatocytes and cholangiocytes grow rapidly and synchronously. In contrast, the vast majority of liver diseases involve a prolonged pathologic duration, therefore multiple types of cells participate and play different roles in the variant stages. However, it is not fully understood how EGFR and Met play their roles in this complicated setting. In this study, we explore the role of MET and EGFR signaling pathways in biliary injury after common bile duct ligation. Mice with inhibition of EGFR signaling alone (EGFRi) showed abolished hepatocyte proliferation and biliary duct cell proliferation (Ki67 immunochemistry staining) at 2, 5, and 7 days after BDL. However, Met knockout mice (KO) showed increased proliferation of cholangiocytes at 2, 5, and 7 days. Met KO mice subjected to BDL surgery had an increase of the CK19‐ marked ductular reaction at 2, 5, and 7 days. In contrast, EGFRi mice showed a reduced ductular reaction at the same time point. There was enhanced immunohistochemistry for Sox9 in EGFRi mice, but absence of its expression in Met KO mice at 7 days post‐BDL. From western blot results of total liver tissue lysate, we found increased EpCAM expression after BDL at 7 days in Met KO but not in EGFRi mice. In addition, we also observed that both p‐Merlin and cleaved p‐Mst1, components of the Hippo pathway, decreased only in Met knockout mice. Mice with combined disruption of Met and EGFR signaling became very ill by 24 hours and died at 1 to 2 days after bile duct ligation. From Kaplan‐Meier analysis, both EGFR inhibition and Met knockout mice had decreased survival rates starting at 11 days, though the survival rate of Met KO mice was overall much better than EGFRi mice by around 40%. We also observed that p‐Ezrin (Thr567) was downregulated in either Met KO or EGFRi mice, while the total Ezrin expression did not change.ConclusionsOur study demonstrates that both c‐Met and EGFR control biliary response to bile duct ligation. The cholangiocyte responses, however, were very different between these two receptors. Their combined disruption led to acute liver failure and early death following bile duct ligation. The receptor tyrosine kinases c‐Met and EGFR may play different roles in the biliary injury‐repair responses, including proliferation, trans‐differentiation, and bi‐potential progenitor cells activation.
Title: Differential responses of receptor tyrosine kinases C‐Met and EGFR in mice
Description:
In previous studies, we have demonstrated the critical roles of EGFR and HGFR (c‐Met) for liver regeneration and for conversion of hepatocytes to cholangiocytes by a “clean” partial hepatectomy model, in which hepatocytes and cholangiocytes grow rapidly and synchronously.
In contrast, the vast majority of liver diseases involve a prolonged pathologic duration, therefore multiple types of cells participate and play different roles in the variant stages.
However, it is not fully understood how EGFR and Met play their roles in this complicated setting.
In this study, we explore the role of MET and EGFR signaling pathways in biliary injury after common bile duct ligation.
Mice with inhibition of EGFR signaling alone (EGFRi) showed abolished hepatocyte proliferation and biliary duct cell proliferation (Ki67 immunochemistry staining) at 2, 5, and 7 days after BDL.
However, Met knockout mice (KO) showed increased proliferation of cholangiocytes at 2, 5, and 7 days.
Met KO mice subjected to BDL surgery had an increase of the CK19‐ marked ductular reaction at 2, 5, and 7 days.
In contrast, EGFRi mice showed a reduced ductular reaction at the same time point.
There was enhanced immunohistochemistry for Sox9 in EGFRi mice, but absence of its expression in Met KO mice at 7 days post‐BDL.
From western blot results of total liver tissue lysate, we found increased EpCAM expression after BDL at 7 days in Met KO but not in EGFRi mice.
In addition, we also observed that both p‐Merlin and cleaved p‐Mst1, components of the Hippo pathway, decreased only in Met knockout mice.
Mice with combined disruption of Met and EGFR signaling became very ill by 24 hours and died at 1 to 2 days after bile duct ligation.
From Kaplan‐Meier analysis, both EGFR inhibition and Met knockout mice had decreased survival rates starting at 11 days, though the survival rate of Met KO mice was overall much better than EGFRi mice by around 40%.
We also observed that p‐Ezrin (Thr567) was downregulated in either Met KO or EGFRi mice, while the total Ezrin expression did not change.
ConclusionsOur study demonstrates that both c‐Met and EGFR control biliary response to bile duct ligation.
The cholangiocyte responses, however, were very different between these two receptors.
Their combined disruption led to acute liver failure and early death following bile duct ligation.
The receptor tyrosine kinases c‐Met and EGFR may play different roles in the biliary injury‐repair responses, including proliferation, trans‐differentiation, and bi‐potential progenitor cells activation.
Related Results
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract
BACKGROUND
Epidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance i...
Abstract A142: Molecular modeling approach to the rational design of promiscuous quinazoline-based EGFR inhibitors
Abstract A142: Molecular modeling approach to the rational design of promiscuous quinazoline-based EGFR inhibitors
Abstract
Solid tumors at the advanced stages are often characterized by the overexpression of tyrosine kinase receptors that stimulate growth through the MAP kinase ...
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
Objectives
Low density lipoprotein receptor defect mice model by transgenetic technology was used to detect atherosclerosis by Ultrasound Biology (UBM). And evalu...
Abstract 2113: KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR
Abstract 2113: KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR
Abstract
Background: The second mutation of T790M in epidermal growth factor receptor (EGFR) exon 20 mediates resistance to first- and second-generation EGFR tyrosin...
Abstract TP356: Renal Function and In-Hospital Outcomes in Patients With Acute Cerebrovascular Disease: Results From Chinese Stroke Center Alliance
Abstract TP356: Renal Function and In-Hospital Outcomes in Patients With Acute Cerebrovascular Disease: Results From Chinese Stroke Center Alliance
Background and Purpose:
To investigate the association of renal function with in-hospital death and recurrent stroke in patients with acute stroke.
...
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract
Purpose: Advanced stage lung adenocarcinoma patients with activating EGFR mutation have better survival result after EGFR tyrosine kinase inhibitor develope...
Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt
Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt
AbstractThe oncogenic epidermal growth factor receptor (EGFR) is commonly overexpressed in solid cancers. The tyrosine kinase activity of EGFR has been a major therapeutic target f...

